MARKET

RDY

RDY

Dr Reddys Labs
NYSE
81.46
+0.62
+0.77%
Opening 12:22 07/26 EDT
OPEN
81.21
PREV CLOSE
80.84
HIGH
81.97
LOW
81.16
VOLUME
82.70K
TURNOVER
0
52 WEEK HIGH
81.97
52 WEEK LOW
63.28
MARKET CAP
13.57B
P/E (TTM)
20.33
1D
5D
1M
3M
1Y
5Y
1D
Dr. Reddy’s Sells Stake to Nestlé India
TipRanks · 2d ago
Dr Reddys Labs: Report of foreign issuer
Press release · 3d ago
Dr. Reddy’s Considers Stock Split Proposal
TipRanks · 3d ago
Weekly Report: what happened at RDY last week (0715-0719)?
Weekly Report · 4d ago
Dr. Reddy’s Unveils VONO™ for India Market
TipRanks · 07/18 18:17
Dr. Reddy’s Confronts GST Demand Order
TipRanks · 07/15 10:51
Weekly Report: what happened at RDY last week (0708-0712)?
Weekly Report · 07/15 09:05
U.S. Senate passes bill to trim Big Pharma "patent thickets"
U.S. Senate passes bill to trim Big Pharma "patent thickets" to hinder generic competition. The bill is intended to ease the entrance of biosimilars and other generic drugs onto the market. The Affordable Prescriptions for Patients Act moves next to the U.s. House for consideration.
Seeking Alpha · 07/12 16:35
More
About RDY
Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.

Webull offers Dr Reddy's Laboratories Ltd (ADR) stock information, including NYSE: RDY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RDY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RDY stock methods without spending real money on the virtual paper trading platform.